Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, Lange JM, Miedema F, Danner SA, Schellekens PT. Pakker NG, et al. Among authors: van leeuwen r. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 15;16(5):318-26. doi: 10.1097/00042560-199712150-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9420308
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CA, Lange JM, Schuitemaker H. van't Wout AB, et al. Among authors: van leeuwen r. J Clin Invest. 1997 Nov 1;100(9):2325-32. doi: 10.1172/JCI119771. J Clin Invest. 1997. PMID: 9410911 Free PMC article.
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.
Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, Schuitemaker H. Koot M, et al. Among authors: van leeuwen r. J Infect Dis. 1999 Jan;179(1):254-8. doi: 10.1086/314539. J Infect Dis. 1999. PMID: 9841850
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM. Wit FW, et al. Among authors: van leeuwen r. J Infect Dis. 1999 Apr;179(4):790-8. doi: 10.1086/314675. J Infect Dis. 1999. PMID: 10068573
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection.
van Leeuwen R, van den Hurk PJ, Jöbsis GJ, van der Wouw PA, Reiss P, Eeftinck Schattenkerk JK, Danner SA, Lange JM. van Leeuwen R, et al. Among authors: van den hurk pj, van der wouw pa. Genitourin Med. 1990 Dec;66(6):418-22. doi: 10.1136/sti.66.6.418. Genitourin Med. 1990. PMID: 2125023 Free PMC article.
384 results